Catalent expands formulation offerings
According to the company, the new OptiForm Solution Suite now includes more comprehensive candidate screening tools, absorption, distribution, metabolism and excretion (ADME) considerations, and in silico drug metabolism and pharmacokinetic (DMPK) modeling.
The suite also includes additional bioavailability enhancing tools, materials for cGLP intravenous and oral toxicological studies, as well as cGMP materials for first-in-human studies.
Commenting on the expected expansion earlier this year at a press briefing, Stephen Tindal, Director, Science & Technology and Technical Support for Optiform Solution Suite, USA, said the company wants to work with companies sooner and take them further.
“[Molecules] shouldn’t die because of formulation,” he said. “We want every molecule to survive.”
Expanding on this in the company’s press release, Julien Meissonnier, Catalent’s vice president, Science and Technology said formulation needs to be guided by a “phase-appropriate model that measures and evaluates the right data at the right time,” in order to ensure a program’s success.
